Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes

Diabetes

Volumn 60, Issue 12, 2011, Pages 3246-3255

  Wang, Xiaojie ^a   Hao, Jianqiang ^a   Metzger, Daniel L ^a   Mui, Alice ^a   Ao, Ziliang ^a   Akhoundsadegh, Noushin ^a   Langermann, Solomon ^b   Liu, Linda ^b   Chen, Lieping ^c   Ou, Dawei ^a   Verchere, C Bruce ^a   Warnock, Garth L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Amplimmune Inc   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 H4; GAMMA INTERFERON; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DIABETES; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; IMMUNE RESPONSE; INCIDENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE; TH17 CELL;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; LYMPH NODES; MICE; MICE, INBRED NOD; PANCREAS; PREDIABETIC STATE; T-LYMPHOCYTES; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 82255185834     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0375     Document Type: Article

References (50)

1. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996;85:291-297 (Pubitemid 26160699)
2. Solomon M, Sarvetnick N. The pathogenesis of diabetes in the NOD mouse. Adv Immunol 2004;84:239-264 (Pubitemid 38887683)
3. Miyazaki A, Hanafusa T, Yamada K, et al. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. Clin Exp Immunol 1985;60:622-630 (Pubitemid 15021367)
4. Gorsuch AN, Spencer KM, Lister J, et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981;2:1363-1365 (Pubitemid 12239439)
5. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447-485 (Pubitemid 40563177)
6. Hayward AR, Shreiber M. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. J Immunol 1989;143:1555-1559 (Pubitemid 19217418)
7. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 1988;240:659-662
8. Charlton B, Mandel TE. Progression from insulitis to beta-cell destruction in NOD mouse requires L3T4+ T-lymphocytes. Diabetes 1988;37:1108-1112 (Pubitemid 19033594)
9. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698 (Pubitemid 34547482)
10. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769 (Pubitemid 40770766)
11. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-2608 (Pubitemid 41007846)
12. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993;42:44-55 (Pubitemid 23013794)
13. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356
14. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008;121:299-306; quiz 307-308
15. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145-1155
16. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431-440
17. van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997;185:393-403 (Pubitemid 27078358)
18. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-547
19. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-988
20. Lühder F, Höglund P, Allison JP, Benoist C, Mathis D. Cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998;187:427-432 (Pubitemid 28080071)
21. Schmidt EM, Wang CJ, Ryan GA, et al. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol 2009;182:274-282
22. Hawiger D, Tran E, Du W, et al. ICOS mediates the development of insulindependent diabetes mellitus in nonobese diabetic mice. J Immunol 2008; 180:3140-3147
23. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198:63-69 (Pubitemid 36870186)
24. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004;199:1479-1489 (Pubitemid 38780403)
25. Dong C, Nurieva RI. Regulation of immune and autoimmune responses by ICOS. J Autoimmun 2003;21:255-260 (Pubitemid 37410113)
26. Sica GL, Choi IH, Zhu G, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003;18:849-861 (Pubitemid 36776432)
27. Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003;18:863-873 (Pubitemid 36776433)
28. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 2003;100:10388-10392 (Pubitemid 37071888)
29. Ou D, Wang X, Metzger DL, et al. Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway. Cell Transplant 2006;15:399-410 (Pubitemid 44320506)
30. Wang X, Hao J, Metzger DL, et al. Local expression of B7-H4 by recombinant adenovirus transduction in mouse islets prolongs allograft survival. Transplantation 2009;87:482-490
31. Suh WK, Wang S, Duncan GS, et al. Generation and characterization of B7- H4/B7S1/B7x-deficient mice. Mol Cell Biol 2006;26:6403-6411
32. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998;280:243-248 (Pubitemid 28178061)
33. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53 (Pubitemid 34293419)
34. Ruperto N, Lovell DJ, Quartier P, et al.; Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-391
35. Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytesmacrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes 1994;43:667-675 (Pubitemid 24138780)
36. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003;171:4040-4047 (Pubitemid 37238678)
37. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871-1878
38. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184:387-396 (Pubitemid 26324092)
39. D'Alise AM, Auyeung V, Feuerer M, et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci USA 2008; 105:19857-19862
40. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66 (Pubitemid 26110755)
41. Balasa B, Krahl T, Patstone G, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997;159:4620-4627 (Pubitemid 127470625)
42. Höglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 1999;189: 331-339 (Pubitemid 29063254)
43. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med 2002;196:369-377 (Pubitemid 34875666)
44. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002;109:131-140 (Pubitemid 34052549)
45. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-699
46. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061 (Pubitemid 36222930)
47. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337-342 (Pubitemid 36432315)
48. Taylor PA, Friedman TM, Korngold R, Noelle RJ, Blazar BR. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002;99:4601-4609 (Pubitemid 34627233)
49. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-1150 (Pubitemid 37173698)
50. Yuan CL, Xu JF, Tong J, et al. B7-H4 transfection prolongs beta-cell graft survival. Transpl Immunol 2009;21:143-149